North America Neurotoxins Market Forecast to 2028

North America Neurotoxins Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product Type (Botox, Dysport, Xenomin, and Others), Application (Therapeutic and Aesthetic), and End User (Hospitals, Specialty Clinics, Dermatology Clinics, and Others)

Send Enquiry

$2,100$3,500

Description

The North America neurotoxins market is expected to grow from US$ 4,801.29 million in 2023 to US$ 8,416.95 million by 2028. It is estimated to grow at a CAGR of 11.9% from 2023 to 2028.

Emergence of Innovative Facial Aesthetic Products Fuels North America Neurotoxins Market

The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of “DTX-021″—a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world’s first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach’s evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the North America neurotoxin market to grow.

North America Neurotoxins Market Overview

The North America neurotoxin market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for neurotoxins. The market growth in the region is attributed to the increasing product launches, growing FDA approvals for neurotoxins for various muscular conditions, rising aging population, increasing numbers of non-surgical or minimally invasive cosmetic procedures, increasing number of aesthetic procedures, and growing demand for minimally invasive therapeutics.

North America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)

North America Neurotoxins Market Segmentation

The North America neurotoxins market is segmented into product type, application, end user, and country. Based on product type, the North America neurotoxins market is sub segmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.

Based on application, the North America neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.

Based on end user, the North America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.

Based on country, the North America neurotoxins market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2023.

AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH & Co KGaA, Metabiologics, and Revance Therapeutics Inc are among the leading companies operating in the North America neurotoxins market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication: